Evidence map›Paper›PMID 41151932›Full record

ArticleJournal of clinical neurology (Seoul, Korea)2025

Olfactory Dysfunction in Patients With Acetylcholine-Receptor-Antibody-Positive Myasthenia Gravis.

Hee Jo Han, Hyun Ji Lyou, Seung Woo Kim, Jung Hwan Lee, Ha Young Shin

Abstract read
In one paragraph

Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hee Jo HanDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9482-9244
Hyun Ji LyouDepartment of Neurology, The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0001-9020-8558
Seung Woo KimDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-5621-0811
Jung Hwan LeeDepartment of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. blubear@hanmail.net.ORCID https://orcid.org/0000-0002-0040-7236
Ha Young ShinDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. hayshin@yuhs.ac.ORCID https://orcid.org/0000-0002-4408-8265

Funding

National Research Foundation of Korea RS-2023-00212125
6 · The paper itself

Abstract

background and purposeMyasthenia gravis (MG) is an antibody-mediated disease characterized by fluctuating muscle weakness and fatigue due to impaired neuromuscular junction transmission. Although primarily considered a motor dysfunction disorder, there is emerging evidence that MG can also present with nonmotor symptoms, including olfactory impairment. However, the prevalence and clinical relevance of olfactory dysfunction in MG remain poorly understood. This study compared olfactory function between MG patients and healthy controls with the aim of identifying clinical factors associated with olfactory impairment in MG.

methodsAcetylcholine receptor (AChR)-antibody-positive MG patients and healthy controls were recruited from a single-center outpatient clinic. Olfactory function was assessed using the KVSS II (Korean version of the Sniffin' Sticks II) test, comprising odor threshold, discrimination, and identification subtests. We compared olfactory function and clinical factors between MG patients and healthy controls after adjusting and matching for age and sex.

resultsThis study enrolled 51 MG patients and 43 healthy controls. Logistic regression analyses revealed that the MG patients had a significantly increased risk of olfactory dysfunction (odds ratio=3.6, 95% confidence interval=1.4-9.1,

conclusionsOlfactory dysfunction was significantly more prevalent in the MG patients than in the healthy controls. These findings highlight the need for further research into the underlying mechanisms and potential clinical implications of olfactory impairment in MG.

Indexed as

myasthenia gravisneurologic autoimmune diseaseolfactory impairmentsmell dysfunction

Identifiers

PMID41151932
PMCPMC12569417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.